Label check: what the current Zepbound prescribing information actually says about dosing
Zepbound's US prescribing information, revised 08/2026, now lists four ways the drug is supplied and records four labeling changes made in 2026, including removal of the suicidal behavior and ideation warning.
The FDA-approved prescribing information for Zepbound (tirzepatide) carries a revision date of 08/2026 and lists four different product presentations, a fixed dose-escalation schedule, and four labeling changes made during 2026 [1].
What the label says about dosing
The recommended starting dosage for all indications is 2.5 mg injected under the skin once weekly for 4 weeks [1]. The label states plainly that "the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage" [1]. After 4 weeks, the dosage increases to 5 mg once weekly, and may then be raised in 2.5 mg increments after at least 4 weeks on the current dose [1]. The label says this schedule is followed "to reduce the risk of gastrointestinal adverse reactions" [1].
Maintenance dosing differs by indication. For weight reduction and long-term maintenance, the recommended maintenance dosage is 5 mg, 10 mg or 15 mg once weekly [1]. For moderate to severe obstructive sleep apnea (OSA) in adults with obesity, it is 10 mg or 15 mg once weekly [1]. The maximum dosage for all indications is 15 mg once weekly [1]. Prescribers are told to consider treatment response and tolerability when choosing a maintenance dosage, and to consider a lower maintenance dosage if a patient does not tolerate one [1].
On missed doses, the label says a dose can be taken as soon as possible within 4 days (96 hours) of the missed dose; if more than 4 days have passed, the missed dose is skipped and the next one taken on the regular day [1]. The weekly injection day can be changed as long as at least 3 days (72 hours) separate two doses [1].
Four presentations, including a multi-dose KwikPen
Dosage forms and strengths now cover a single-dose pen, a single-dose vial, a multi-dose vial and a single-patient-use KwikPen [1]. Single-dose pens and vials come in 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL [1]. The multi-dose vial and KwikPen each contain four doses of a single strength in 2.4 mL — for example, 40 mg/2.4 mL (16.7 mg/mL) delivering four 10 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) delivering four 15 mg/0.6 mL doses [1].
Because there are now several delivery systems, the label added an instruction under Dosage and Administration (2.4), dated 01/2026, telling clinicians to inform patients and caregivers which presentation they will receive, to train them on that specific device, and to retrain them and point them to the new Instructions for Use if the presentation changes [1]. A separate warning, section 5.10, says never share a Zepbound KwikPen between patients, even if the pen needle is changed [1]. The label also states the KwikPen is not recommended for self-administration by certain patients; the full list of those exceptions is cut off in the text reviewed here [1].
Recent major changes
The label's Recent Major Changes box lists four 2026 updates: the administration instructions (01/2026), severe gastrointestinal adverse reactions (02/2026), removal of the suicidal behavior and ideation warning (02/2026), and diabetic retinopathy complications in patients with type 2 diabetes (08/2026) [1]. The gastrointestinal warning says Zepbound "is not recommended in patients with severe gastroparesis" [1]. The retinopathy section tells prescribers to monitor patients with a history of diabetic retinopathy for progression [1]. The boxed warning about thyroid C-cell tumors in rats remains, along with contraindications for personal or family history of medullary thyroid carcinoma or MEN 2 [1].
Why it matters for patients
Label text is what pharmacists, prescribers and many insurers work from. Two practical points stand out. First, the OSA indication has a higher floor than the weight indication: 10 mg is the lowest recommended maintenance dose for sleep apnea, versus 5 mg for weight [1]. Second, multi-dose devices hold four doses of one strength [1], so a dose change means a different device, not a different amount drawn from the same one.
The removal of the suicidal behavior and ideation warning in 02/2026 is a documented labeling change [1]; the reasoning behind it is not stated in the label itself.
What happens next
The label's clinical studies section is titled "Weight Reduction and Long-Term Maintenance Studies in Adults with Obesity or Overweight" [1]. Which specific trials it summarizes is not visible in the portion reviewed, so whether newer maintenance data have been incorporated is not yet known from this document. Labels are revised without notice; the revision date, currently 08/2026, is the way to check [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.